Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
村上 昌雄*; 菱川 良夫*; 宮島 悟史*; 岡崎 良子; Sutherland, K.*; 阿部 光幸*; Bulanov, S. V.; 大道 博行; Esirkepov, T. Z.; Koga, J. K.; et al.
AIP Conference Proceedings 1024, p.275 - 300, 2008/08
光医療研究連携センターで進める事業の中心的治療器の開発の概念について考えを提示する。
村上 昌雄*; 出水 祐介*; 丹羽 康江*; 永山 伸一*; 前田 拓也*; 馬場 理師*; 宮脇 大輔*; 寺嶋 千貴*; 有村 健*; 美馬 正幸*; et al.
no journal, ,
The Hyogo Ion Beam Medical Center was established in May 2001, a leading project of the "Hyogo Cancer Strategy". The accelerator is a synchrotron that can accelerate proton and carbon ion beams at a maximum of 230 and 320 MeV/u, respectively, and the maximum ranges in water are 300 and 200 mm, respectively. Three irradiation rooms installed with 45-degree, horizontal/vertical, and horizontal fixed ports can be used for carbon ion radiation therapy, and 2 gantry rooms can be additionally used for proton beams. Particle beam radiation therapy had been performed in 2,639 patients as of the end of March 2009. The diseases treated were prostate cancer, head and neck tumors, liver cancer, lung cancer, and bone soft tissue tumors, in decreasing order of frequency, and these 5 major diseases accounted for 87% of the cases. As the current problems of particle beam radiation therapy, the effect of the differential use of proton and carbon ion beams is unclear, adverse events, such as skin disorders, may occur due to the limitation of the broad beam method, and the necessity to install large-scale devices is an obstacle to its dissemination. We are aiming at the development and clinical application of a laser-driven proton radiotherapy device in cooperation with the Japan Atomic Energy Agency.
Bolton, P.; 阿部 光幸*; 赤城 卓*; Nuesslin, F.*; 堀 利彦; 岩下 芳久*; 河西 俊一; 近藤 公伯; 前田 拓也; Molls, M.*; et al.
no journal, ,
The rapid advancement of high power laser technology combined with laser-accelerated ion yields from intense laser-plasma interactions sustains a strong interest in the development of integrated laser-driven ion accelerator systems (ILDIAS) that can be used for laser-driven ion beam radiotherapy (L-IBRT). A prime motivation is the promise of significantly reduced size and cost that would afford much greater patient access. Bunch duration of several nanoseconds and high peak current (with a low duty factor) make laser-driven ion irradiation unique. En route to a compact laser-driven "clinical" radiotherapeutic facility it is essential to develop multipurpose "preclinical" or test beamlines that can be used for (1) testing suitable transport optics, diagnostics and control instrumentation, (2) medical and radiobiological studies at the cellular level and in tissue to validate the radiobiological effectiveness of laser-driven ion beam radiotherapy and (3) applications to nonmedical science and technology. Preclinical and clinical beamline development calls for delivering proton energies near 50 MeV and at least 80 MeV respectively with beam energy spread and dose accuracy at one to few percent levels. Control instrumentation and diagnostics capable of single bunch resolution at required repetition rates will be essential to verify and optimize ILDIAS machine performance and capability. In the context of L-IBRT we will discuss the ILDIAS concept as well as beam delivery and instrumentation requirements.